AstraZeneca has selected Agentforce Life Sciences for Customer Engagement to help transform its global customer engagement. In this way, the company wants to foster stronger relationships with healthcare professionals through interaction based on data and driven by artificial intelligence. This step supports AstraZeneca’s commitment to push the boundaries of science and deliver life-changing medicines in oncology, rare diseases and biopharmaceuticals, including cardiovascular, renal and metabolic, as well as respiratory and immunological.

With Agentforce Life Sciences, Salesforce wants to help AstraZeneca usher in a new era of intelligent engagement, redefining customer relationships and accelerating business growth. This partnership will allow teams to focus on strategic customer outcomes and the most meaningful customer interactions.

More advantages for AstraZeneca

Expanding its scope for AstraZeneca, Salesforce will support Agentforce 360 ​​for Life Sciences as the global, comprehensive customer engagement solution for AstraZeneca, including:

  • Medical-commercial coordination: Consolidation of the knowledge of health professionals and superficial context between teams.
  • Custom interaction: Expanded operations across key account, reimbursement and field teams with recommendations on best course of action. AstraZeneca will also coordinate and automate digital campaigns across multiple channels based on customer preferences.
  • Model Context Protocol (MCP) Interoperability: By extending its composable architecture with Salesforce’s Mulesoft Agent Fabric, AstraZeneca will coordinate the actions of internal and external agents across field work, business operations, and across brands and regions, enabling its service teams and AI agents to work seamlessly together.

“This partnership with AstraZeneca represents a clear step towards creating intelligent and proactive customer engagement in healthcare and science, with their choice of Agentforce Life Sciences for Customer Engagement,” he said. Frank Defesche, Senior Vice President and General Manager of Life Sciences at Salesforce. “Together, we will equip AstraZeneca teams with the latest technology to deliver personalized engagement and accelerate the delivery of life-changing medicines to patients around the world.”

Alex Chen
Alex Chen

Alex Chen serves as the chief editor of Asia Tech Journal, bringing over a decade of experience in technology journalism. Previously writing for several globally renowned publications, Alex is celebrated for his insightful analyses and in-depth reporting on tech trends across Asia. Passionate about innovation, Alex specializes in the dynamic technology ecosystem of China and its global impacts.